Abstract 6126
Background
Identification of clinically actionable mutations in cancer is essential for catalyzing precision oncology based on risk stratification. Currently, little is known about the mutation profile of high-risk acute lymphoblastic leukemia (ALL) in Korean patients. We aimed to develop a multigene panel for ALL and to investigate clinically actionable mutations in the Korean patients with high-risk ALL.
Methods
We developed a multigene panel targeting 102 genes with diagnostic, prognostic, or therapeutic significance in ALL and validated it using reference materials and clinical samples. The mutation analyses were done in a total of 18 patients with high-risk ALL {T lymphoblastic leukemia (T-ALL, n = 7), B lymphoblastic leukemia in relapse (relapsed B-ALL, n = 5), and Philadelphia chromosome-positive ALL (Ph+ ALL, n = 6)}. High-risk ALL was categorized based on clinical findings and laboratory tests including immunophenotyping, chromosome analyses, fluorescence in situ hybridization, and RT-PCR. Clinically actionable mutations were selected based on a four-tiered system recommended by Association for Molecular Pathology in 2017.
Results
A total of 28 clinically actionable mutations including 6 novel mutations were identified in 83% of the patients. The most frequent alterations in Korean patients were loss of function mutations of KMT2C (78%), followed by mutations of NOTCH1 (17%) and SUZ12 (11%). There is no difference in the frequency of KMT2C mutation among T-ALL, relapsed B-ALL, and Ph+ ALL, while mutations in NOTCH1 and SUZ12 were observed only in T-ALL. Additional 8 genes including NT5C2 and KRAS were mutated. Furthermore, potential germline pathogenic variants were discovered in 3 patients including one previously diagnosed as neurofibromatosis type 1.
Conclusions
This study showed that KMT2C mutations were recurrently observed in Korean patients with high-risk ALL. The KMT2C mutation status could be an effective risk stratification strategy for Korean patients with ALL. This study provides clinically actionable mutational portrait of high-risk ALL, albeit in a limited number of patients and gives novel insight into genetic heterogeneity of the disease.
Clinical trial identification
Legal entity responsible for the study
Pusan National University Yangsan Hospital Institutional Review Board.
Funding
Biomedical Research Institute in Pusan National University Yangsan Hospital.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract